A woman outside standing by the stairs looking at her cellphone.

*HUMIRA® (adalimumab) is approved for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and children 2 years of age and older.

Reasons to consider HUMIRA as an option in treating non-infectious uveitis*

Icon of a woman

HUMIRA is the first FDA-approved biologic proven to treat non-infectious intermediate, posterior, and panuveitis in adults and children 2 years of age and older.

A circle with a X mark and check mark inside depicting that HUMIRA is a different way to treat non-infectious uveitis.

HUMIRA is a whole different way to treat non-infectious uveitis.* It is not a steroid.

                                                                                     

Target icon

HUMIRA targets and blocks a specific source of inflammation that plays a role in
non-infectious uveitis.*

 

When to consider HUMIRA as a treatment option

Your doctor may prescribe HUMIRA if:

  • you are not responding to or can’t tolerate other treatments.
  • steroid treatments are not working.
  • you’ve been on moderate or high doses of corticosteroids for more than 1 month.

HUMIRA increased the time non-infectious uveitis* was controlled

In a study of adult patients with active, non-infectious intermediate, posterior, and panuveitis, disease control was defined by 4 combined measurements—the first 3 contribute to what’s commonly known as a flare:

Number 1 inside of a circle.

Vitreous haze (cloudiness in the middle of the eye).

Number 2 inside of a circle.

Inflammatory cells in the front of the eye.

Number 3 inside of a circle

New lesions on the back of the eye.

Number 4 inside of a circle

Maintenance of visual clarity (ability to read an eye chart at a distance).

In the same clinical study of adult patients with active disease

50% number inside of a half circle

HUMIRA patients experienced 50% decreased risk of a combination of flare and loss of visual clarity.

Number 6 inside of a broken line circle

Differences in disease control were seen as early as 6 weeks for patients taking HUMIRA.

Treating non-infectious uveitis* in children 2 and older

In a clinical study of children 2 years of age and older with non-infectious uveitis* who had been previously diagnosed with Juvenile Idiopathic Arthritis (JIA), HUMIRA in combination with another drug called methotrexate (MTX) was proven to increase the time non-infectious uveitis* was controlled.

50% number inside of a half circle

75% decreased risk of treatment failure compared to MTX alone.

 

 

Number 6 inside of a broken line circle

HUMIRA is not a steroid, and can reduce topical steroid use in children 2 and older with non-infectious uveitis.*

 

*HUMIRA (adalimumab) is approved for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and children 2 years of age and older.

Has your child been prescribed HUMIRA?

What to expect